SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2016
This article has no abstract
Epistemonikos ID: debbb813590a9524b1ea76dbf9c1e0bb848cf59b
First added on: Apr 01, 2023